PDF(Pubmed)
Abstract：
Molecular genetic events are among the numerous factors affecting the clinical course of papillary thyroid carcinoma (PTC). Recent studies have demonstrated that aberrant expression of miRNA, as well as different thyroid-related genes, correlate with the aggressive clinical course of PTC and unfavorable treatment outcomes, which opens up new avenues for using them in the personalization of the treatment strategy for patients with PTC. In the present work, our goal was to assess the applicability of molecular markers in the preoperative diagnosis of aggressive variants of papillary thyroid cancer. The molecular genetic profile (expression levels of 34 different markers and BRAF mutations) was studied for 108 cytology specimens collected by fine-needle aspiration biopsy in patients with PTC having different clinical manifestations. Statistically significant differences with adjustment for multiple comparisons (p < 0.0015) for clinically aggressive variants of PTC were obtained for four markers: miRNA-146b, miRNA-221, fibronectin 1 (FN1), and cyclin-dependent kinase inhibitor 2A (CDKN2A) genes. A weak statistical correlation (0.0015 < p < 0.05) was observed for miRNA-31, -375, -551b, -148b, -125b, mtDNA, CITED1, TPO, HMGA2, CLU, NIS, SERPINA1, TFF3, and TMPRSS4. The recurrence risk of papillary thyroid carcinoma can be preoperatively predicted using miRNA-221, FN1, and CDKN2A genes.
摘要：
分子遗传事件是影响甲状腺乳头状癌（PTC）临床病程的众多因素之一。最近的研究表明，miRNA的异常表达，以及不同的甲状腺相关基因，与PTC的积极临床过程和不利的治疗结果相关，这为在PTC患者的个性化治疗策略中使用它们开辟了新的途径。在目前的工作中,我们的目标是评估分子标志物在甲状腺乳头状癌术前侵袭性变异诊断中的适用性.研究了通过细针穿刺活检收集的108个具有不同临床表现的PTC患者的细胞学标本的分子遗传谱（34种不同标志物和BRAF突变的表达水平）。对于PTC的临床侵袭性变体的多重比较调整(p<0.0015)的统计学显著差异获得了四个标志物:miRNA-146b,miRNA-221，纤连蛋白1（FN1），和细胞周期蛋白依赖性激酶抑制剂2A（CDKN2A）基因。观察到miRNA-31，-375，-551b的弱统计相关性（0.0015
